View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPhaseBio Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 PhaseBio Pharmaceuticals 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Jun 2022최근 과거 실적 업데이트Reported Earnings • Mar 17Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)Full year 2020 results: Net loss: US$98.6m (loss widened 151% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1모든 업데이트 보기Recent updates공시 • Aug 16PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 18PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 15Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.The US Bankruptcy Court conditionally approved the modified first amended plan and disclosure statement of PhaseBio Pharmaceuticals, Inc. on May 13, 2024. The debtor had filed its amended disclosure statement in the Court on May 13, 2024. May 13, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is June 17, 2024. The confirmation hearing for the plan has been scheduled for June 26, 2024.공시 • Apr 03PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/02/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 26PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/25/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 18Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.Chiesi Farmaceutici S.p.A. entered into an agreement to acquire all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab for $100 million on November 4, 2022. As per the terms of the transaction, $40 million in cash to be paid at the closing of the Transaction (subject to adjustment), plus future contingent payments of up to $60 million (the “Milestone Payments”) in cash upon the completion of certain regulatory milestone events. Chiesi is required to deposit $4 million (the “Deposit Funds”) with an escrow agent within three business days after the execution of the Agreement, which amount will be credited against the purchase price payable by Chiesi upon the closing of the Transaction. PhaseBio will be required to pay Chiesi a break-up fee of $2 million. The Transaction, and the designation of Chiesi as the stalking horse bidder, is subject to the approval of the Bankruptcy Court. The completion of the Transaction is subject to a number of customary conditions, including that a specified number of required employees shall have accepted and not rescinded offers of employment or engagement as a consultant or independent contractor with Chiesi and any waiting period applicable to the transaction under any Antitrust Law shall have expired or been terminated. As of January 5, 2023, the transaction has received the approval from the bankruptcy court. Christian E. Plaza of Cooley LLP acted as legal advisor to PhaseBio. Heyward D. Armstrong and Justin G. Truesdale of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and A. Lee Hogewood III and John R. Gardner of K&L Gates LLP both acted as legal advisors to Chiesi. Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab on January 17, 2023.Price Target Changed • Sep 28Price target increased to US$18.00Up from US$14.33, the current price target is an average from 5 analysts. New target price is 6,904% above last closing price of US$0.26. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$1.22 next year compared to a net loss per share of US$2.98 last year.Major Estimate Revision • Aug 19Consensus revenue estimates fall by 68%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.47m to US$3.06m. Forecast losses increased from -US$1.07 to -US$1.22 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$13.67 unchanged from last update. Share price fell 5.0% to US$1.13 over the past week.Seeking Alpha • Aug 12PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29MPhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q2 GAAP EPS of -$0.34 misses by $0.03. Revenue of $0.21M (-98.0% Y/Y) misses by $0.29M. Shares -0.86% PM.Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.7m to US$9.47m. EPS estimate increased from -US$2.03 to -US$1.07 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 13% to US$0.81 over the past week.Price Target Changed • Apr 27Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 5 analysts. New target price is 1,191% above last closing price of US$1.11. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$2.03 next year compared to a net loss per share of US$2.98 last year.Price Target Changed • Dec 16Price target increased to US$16.00Up from US$14.00, the current price target is an average from 5 analysts. New target price is 599% above last closing price of US$2.29. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$2.65 next year compared to a net loss per share of US$3.39 last year.Recent Insider Transactions Derivative • Nov 11Independent Director exercised options to buy US$116k worth of stock.On the 8th of November, Nancy Hutson exercised options to buy 34k shares at a strike price of around US$2.49, costing a total of US$84k. This transaction amounted to 844% of their direct individual holding at the time of the trade. Since March 2021, Nancy's direct individual holding has increased from 1.00k shares to 4.00k. Company insiders have collectively bought US$224k more than they sold, via options and on-market transactions, in the last 12 months.Executive Departure • Sep 16Independent Director Peter Klein has left the companyOn the 14th of September, Peter Klein's tenure as Independent Director ended after 11.8 years in the role. As of June 2021, Peter still personally held only 2.30k shares (US$8.6k worth at the time). Peter is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.33 years.Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.08m to US$10.8m. EPS estimate fell from -US$2.31 to -US$2.56 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 9.3% to US$3.03 over the past week.분석 기사 • Aug 10PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Major Estimate Revision • Jun 19Consensus revenue estimates increase to US$4.07mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$67.2k to US$4.07m. Forecast losses expected to reduce from -US$2.41 to -US$2.31 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target down from US$14.00 to US$12.75. Share price was steady at US$3.75 over the past week.Price Target Changed • Jun 19Price target decreased to US$12.75Down from US$14.00, the current price target is an average from 5 analysts. New target price is 240% above last closing price of US$3.75. Stock is down 26% over the past year.Major Estimate Revision • May 20Consensus EPS estimates increase to -US$2.31The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$76.8k to US$84.0k. EPS estimate increased from -US$2.74 to -US$2.31. Biotechs industry in the US expected to see average net income decline 6.3% next year. Consensus price target of US$14.00 unchanged from last update. Share price rose 14% to US$3.19 over the past week.Major Estimate Revision • Mar 23Consensus revenue estimates fall to US$76.8kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$353.2k to US$76.8k. Forecast losses increased from -US$2.44 to -US$2.74 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$13.50 to US$15.00. Share price fell 3.2% to US$3.88 over the past week.Price Target Changed • Mar 19Price target increased to US$15.00Up from US$13.50, the current price target is an average from 5 analysts. New target price is 287% above last closing price of US$3.88. Stock is up 34% over the past year.Reported Earnings • Mar 17Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)Full year 2020 results: Net loss: US$98.6m (loss widened 151% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1분석 기사 • Mar 04What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?A look at the shareholders of PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) can tell us which group is most powerful...Is New 90 Day High Low • Feb 09New 90-day high: US$4.45The company is up 30% from its price of US$3.41 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.분석 기사 • Jan 08If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%This week we saw the PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) share price climb by 21%. But that doesn't change...Price Target Changed • Jan 07Price target lowered to US$13.50Down from US$14.75, the current price target is an average from 5 analysts. The new target price is 263% above the current share price of US$3.72. As of last close, the stock is down 32% over the past year.Is New 90 Day High Low • Dec 16New 90-day high: US$4.44The company is up 27% from its price of US$3.49 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Dec 01New 90-day high: US$3.80The company is up 2.0% from its price of US$3.72 on 01 September 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Major Estimate Revision • Nov 26Analysts lower revenue estimates to US$296.0kThe 2020 consensus revenue estimate decreased from US$375.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.02 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 7.0% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is up 3.4% to US$3.69 over the past week.Major Estimate Revision • Nov 19Analysts lower revenue estimates to US$375.0kThe 2020 consensus revenue estimate decreased from US$538.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.08 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is down by 2.7% to US$3.57 over the past week.Analyst Estimate Surprise Post Earnings • Nov 14Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 21%. Over the next year, revenue is expected to shrink by 73% compared to a 397% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Oct 24New 90-day low: US$3.10The company is down 34% from its price of US$4.68 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.매출 및 비용 세부 내역PhaseBio Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:PHAS.Q 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 221-10317031 Mar 2211-11517031 Dec 2111-13116030 Sep 2111-11815030 Jun 2110-11214031 Mar 210-11113031 Dec 200-9913030 Sep 201-8013030 Jun 201-6613031 Mar 202-4712031 Dec 192-3911030 Sep 192-3310030 Jun 192-298031 Mar 191-276031 Dec 181-245030 Sep 180-223030 Jun 180-163-331 Mar 180-122-131 Dec 170-1020양질의 수익: PHAS.Q가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 PHAS.Q의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 PHAS.Q의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: PHAS.Q의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: PHAS.Q의 지난 해 수익 증가율이 Biotechs 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: PHAS.Q는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/09/12 19:55종가2024/09/12 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PhaseBio Pharmaceuticals, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrew FeinH.C. Wainwright & Co.Chad MesserNeedham & CompanyAnnabel SamimyStifel, Equities Research2명의 분석가 더 보기
Reported Earnings • Mar 17Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)Full year 2020 results: Net loss: US$98.6m (loss widened 151% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1
공시 • Aug 16PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/15/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 18PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 15Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc.The US Bankruptcy Court conditionally approved the modified first amended plan and disclosure statement of PhaseBio Pharmaceuticals, Inc. on May 13, 2024. The debtor had filed its amended disclosure statement in the Court on May 13, 2024. May 13, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is June 17, 2024. The confirmation hearing for the plan has been scheduled for June 26, 2024.
공시 • Apr 03PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filingOn 04/02/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 11/15/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 26PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 08/25/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 17PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filingOn 05/16/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 18Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab.Chiesi Farmaceutici S.p.A. entered into an agreement to acquire all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab for $100 million on November 4, 2022. As per the terms of the transaction, $40 million in cash to be paid at the closing of the Transaction (subject to adjustment), plus future contingent payments of up to $60 million (the “Milestone Payments”) in cash upon the completion of certain regulatory milestone events. Chiesi is required to deposit $4 million (the “Deposit Funds”) with an escrow agent within three business days after the execution of the Agreement, which amount will be credited against the purchase price payable by Chiesi upon the closing of the Transaction. PhaseBio will be required to pay Chiesi a break-up fee of $2 million. The Transaction, and the designation of Chiesi as the stalking horse bidder, is subject to the approval of the Bankruptcy Court. The completion of the Transaction is subject to a number of customary conditions, including that a specified number of required employees shall have accepted and not rescinded offers of employment or engagement as a consultant or independent contractor with Chiesi and any waiting period applicable to the transaction under any Antitrust Law shall have expired or been terminated. As of January 5, 2023, the transaction has received the approval from the bankruptcy court. Christian E. Plaza of Cooley LLP acted as legal advisor to PhaseBio. Heyward D. Armstrong and Justin G. Truesdale of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and A. Lee Hogewood III and John R. Gardner of K&L Gates LLP both acted as legal advisors to Chiesi. Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab on January 17, 2023.
Price Target Changed • Sep 28Price target increased to US$18.00Up from US$14.33, the current price target is an average from 5 analysts. New target price is 6,904% above last closing price of US$0.26. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$1.22 next year compared to a net loss per share of US$2.98 last year.
Major Estimate Revision • Aug 19Consensus revenue estimates fall by 68%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.47m to US$3.06m. Forecast losses increased from -US$1.07 to -US$1.22 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$13.67 unchanged from last update. Share price fell 5.0% to US$1.13 over the past week.
Seeking Alpha • Aug 12PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29MPhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q2 GAAP EPS of -$0.34 misses by $0.03. Revenue of $0.21M (-98.0% Y/Y) misses by $0.29M. Shares -0.86% PM.
Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.7m to US$9.47m. EPS estimate increased from -US$2.03 to -US$1.07 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 13% to US$0.81 over the past week.
Price Target Changed • Apr 27Price target decreased to US$14.33Down from US$16.00, the current price target is an average from 5 analysts. New target price is 1,191% above last closing price of US$1.11. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$2.03 next year compared to a net loss per share of US$2.98 last year.
Price Target Changed • Dec 16Price target increased to US$16.00Up from US$14.00, the current price target is an average from 5 analysts. New target price is 599% above last closing price of US$2.29. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$2.65 next year compared to a net loss per share of US$3.39 last year.
Recent Insider Transactions Derivative • Nov 11Independent Director exercised options to buy US$116k worth of stock.On the 8th of November, Nancy Hutson exercised options to buy 34k shares at a strike price of around US$2.49, costing a total of US$84k. This transaction amounted to 844% of their direct individual holding at the time of the trade. Since March 2021, Nancy's direct individual holding has increased from 1.00k shares to 4.00k. Company insiders have collectively bought US$224k more than they sold, via options and on-market transactions, in the last 12 months.
Executive Departure • Sep 16Independent Director Peter Klein has left the companyOn the 14th of September, Peter Klein's tenure as Independent Director ended after 11.8 years in the role. As of June 2021, Peter still personally held only 2.30k shares (US$8.6k worth at the time). Peter is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.33 years.
Major Estimate Revision • Aug 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.08m to US$10.8m. EPS estimate fell from -US$2.31 to -US$2.56 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 9.3% to US$3.03 over the past week.
분석 기사 • Aug 10PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Major Estimate Revision • Jun 19Consensus revenue estimates increase to US$4.07mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$67.2k to US$4.07m. Forecast losses expected to reduce from -US$2.41 to -US$2.31 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target down from US$14.00 to US$12.75. Share price was steady at US$3.75 over the past week.
Price Target Changed • Jun 19Price target decreased to US$12.75Down from US$14.00, the current price target is an average from 5 analysts. New target price is 240% above last closing price of US$3.75. Stock is down 26% over the past year.
Major Estimate Revision • May 20Consensus EPS estimates increase to -US$2.31The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$76.8k to US$84.0k. EPS estimate increased from -US$2.74 to -US$2.31. Biotechs industry in the US expected to see average net income decline 6.3% next year. Consensus price target of US$14.00 unchanged from last update. Share price rose 14% to US$3.19 over the past week.
Major Estimate Revision • Mar 23Consensus revenue estimates fall to US$76.8kThe consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$353.2k to US$76.8k. Forecast losses increased from -US$2.44 to -US$2.74 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$13.50 to US$15.00. Share price fell 3.2% to US$3.88 over the past week.
Price Target Changed • Mar 19Price target increased to US$15.00Up from US$13.50, the current price target is an average from 5 analysts. New target price is 287% above last closing price of US$3.88. Stock is up 34% over the past year.
Reported Earnings • Mar 17Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019)Full year 2020 results: Net loss: US$98.6m (loss widened 151% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1
분석 기사 • Mar 04What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?A look at the shareholders of PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) can tell us which group is most powerful...
Is New 90 Day High Low • Feb 09New 90-day high: US$4.45The company is up 30% from its price of US$3.41 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period.
분석 기사 • Jan 08If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%This week we saw the PhaseBio Pharmaceuticals, Inc. ( NASDAQ:PHAS ) share price climb by 21%. But that doesn't change...
Price Target Changed • Jan 07Price target lowered to US$13.50Down from US$14.75, the current price target is an average from 5 analysts. The new target price is 263% above the current share price of US$3.72. As of last close, the stock is down 32% over the past year.
Is New 90 Day High Low • Dec 16New 90-day high: US$4.44The company is up 27% from its price of US$3.49 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Dec 01New 90-day high: US$3.80The company is up 2.0% from its price of US$3.72 on 01 September 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Major Estimate Revision • Nov 26Analysts lower revenue estimates to US$296.0kThe 2020 consensus revenue estimate decreased from US$375.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.02 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 7.0% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is up 3.4% to US$3.69 over the past week.
Major Estimate Revision • Nov 19Analysts lower revenue estimates to US$375.0kThe 2020 consensus revenue estimate decreased from US$538.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.08 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is down by 2.7% to US$3.57 over the past week.
Analyst Estimate Surprise Post Earnings • Nov 14Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 21%. Over the next year, revenue is expected to shrink by 73% compared to a 397% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Oct 24New 90-day low: US$3.10The company is down 34% from its price of US$4.68 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.